Boston Scientific BSX
-
Fair Value Increase, but ResMed Still Expensive
… equity Morningstar uses to value other global medical device companies such as Medtronic MDT, St. Jude STJ and Boston Scientific BSX . The lower cost of equity increases our fair value estimate from USD 40 to USD 45. In addition to the impact …
-
New Morningstar Analyst Report for ResMed Inc. (0C000008SB - USA)
… companies such as Medtronic MDT, St. Jude STJ and Boston Scientific BSX . In fiscal 2013, we expect innovation and continued ..... device companies such as Medtronic, St Jude and Boston Scientific . In fiscal 2013, we expect innovation and continued …
-
Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates
By Robert Honeywill : In Part I of "Johnson & Johnson: At The Crossroads", it was determined that a dividend growth rate of 8.2% was sustainable for at least the next 15 years even if net income growth rate remained around the projected 6%. In Part II , it was determined that Johnson & Johnson ( ...
-
Boston Scientific ([[ BSX ]] -1%) slides in spite of reporting positive results earlier today from a pre-specified analysis of the first 60 patients enrolled in its trial evaluating the performance and ...
Boston Scientific ( BSX -1% ) slides in spite of reporting positive results earlier today from a pre-specified analysis of the first 60 patients enrolled …
-
Boston Scientific ([[ BSX ]] +0.4%) says five-year data from its Asthma Intervention Research 2 clinical trial presented today demonstrated that the Alair Bronchial Thermoplasty System continues to ...
Boston Scientific ( BSX +0.4% ) says five-year data from its Asthma Intervention Research 2 clinical trial presented today demonstrated that the …
-
New Morningstar Analyst Report - Medtronic
… stent was a disappointment. The firm received domestic regulatory approval for its own stent in 2008, long after Boston Scientific BSX and Johnson & Johnson JNJ established footprints in that market. Further exacerbating the situation, Medtronic's …
-
Cramer's Mad Money - 17 Things To Watch In The Week Ahead (5/17/13)
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday May 17. 17 Things To Watch In The Week Ahead: Campbell Soup ( CPB ), Best Buy ( BBY ), AutoZone ( AZO ), Home Depot ( HD ), TJX Companies ( TJX ), NetApp ( NTAP ), Target ( TGT ),
-
Johnson & Johnson: At The Crossroads - Part III
By Robert Honeywill : In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was
-
New Data On Boston Scientific's Atrial Fibrillation Watchman Device Could Lift Outlook
By Trefis : Boston Scientific 's ( BSX ) stock rallied over 5% on Thursday after the medical device ..... fibrillation patients. This could come as a major boost for Boston Scientific , which has been grappling with declining sales and market …
-
Johnson & Johnson: At The Crossroads - Part II
By Robert Honeywill : Part I of this series on Johnson & Johnson ( JNJ ) mainly addressed the sustainability of an increasing dividend payout ratio. If current projections for dividend growth rate remained at 8.2% per year and those for net income growth rate at ~6% per year, it was shown to be ...